151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CytomX Therapeutics Enters Underwriting Agreement for 45.99M Shares
Announces 2025 Financial Results and Provides Business Update
Announces Third Quarter 2025 Financial Results and Provides Business Update
Other Events
Financial Results, Press Release
News, Material Contracts
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload